论文部分内容阅读
目的探讨影响恩度联合化疗治疗中晚期非小细胞肺癌(NSCLC)疗效的相关因素。方法回顾性分析2008年1月至2012年12月接受治疗的60例中晚期NSCLC患者的临床资料,根据肿瘤近期疗效评价标准,分为试验组(34例)和对照组(24例)。试验组为完全缓解和部分缓解的患者,对照组为稳定和肿瘤进展的患者,比较两组患者的相关因素。结果单因素方差分析显示,TNM分期、T分期和肿瘤体积与恩度联合化疗疗效有关(均P<0.05)。Logistic分析显示,TNM分期、T分期和肿瘤体积为影响恩度联合化疗疗效的独立因素。结论 TNM分期、T分期和肿瘤病灶体积是恩度联合化疗治疗中晚期NSCLC疗效的影响因素。
Objective To investigate the factors influencing the efficacy of Endoth combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods The clinical data of 60 patients with advanced non-small cell lung cancer (NSCLC) treated from January 2008 to December 2012 were retrospectively analyzed. According to the evaluation criteria of short-term effect of tumor, the patients were divided into experimental group (34 cases) and control group (24 cases). The patients in the experimental group were those with complete remission and partial remission, the control group with stable and tumor progression, and the relative factors in both groups were compared. Results One-way ANOVA showed that the TNM staging, T staging and tumor volume were associated with the efficacy of combined treatment with Endostar (all P <0.05). Logistic analysis showed that TNM staging, T staging and tumor volume were the independent factors influencing the efficacy of entecavir combined with chemotherapy. Conclusions TNM staging, T staging and tumor volume are the influencing factors for the efficacy of Endo combined with chemotherapy for advanced NSCLC.